Full interview: Q BioMed successfully synthesizes molecule to treat liver cancer in a 'tremendously exciting achievement'
Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive that the New York-based biotech, together with India-based research organization Chemveda Life Sciences, has made a breakthrough with its therapy as a potential chemotherapy to treat liver cancer.
Corin says the molecule called Uttroside-B, is in pre-clinical development, and the company looks forward to submit it as an investigational new drug in 1Q of 2020.
Quick facts: Q BioMed Inc
Market Cap: $11.15 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc named herein, including the promotion by the Company of Q BioMed Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE